FDA
-
-
-
-
-
-
-
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
-
-
-
-
-
-
-
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
-
-
-
-
-
-
-
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab (ZLAB) Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
-
-
-
-
-
-
-
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
-
-
-
-
-
-
-
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
-
-
-
-
-
-
-
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

